Anti-proliferative effect of Fe(III) complexed with 1-(2-hydroxy-3-methoxybenzaldehyde)-4-aminosalicylhydrazone in HepG2 cells

[1]  P. Roy,et al.  Design, spectral characterization, anti-tumor and anti-inflammatory activity of triorganotin(IV) hydroxycarboxylates, apoptosis inducers: In vitro assessment of induction of apoptosis by enzyme, DNA-fragmentation, acridine orange and comet assays , 2014 .

[2]  L. Tesoriere,et al.  Synthesis, spectroscopic characterization and antiproliferative activity of two platinum(II) complexes containing N-donor heterocycles , 2014 .

[3]  Kamran T. Mahmudov,et al.  Di- and tri-organotin(IV) complexes of arylhydrazones of methylene active compounds and their antiproliferative activity , 2014 .

[4]  M. Alexandrov,et al.  Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents , 2014, Biotechnology, biotechnological equipment.

[5]  N. Çolak,et al.  Spectroscopic, antiproliferative and antiradical properties of Cu(II), Ni(II), and Zn(II) complexes with amino acid based Schiff bases , 2014, Medicinal Chemistry Research.

[6]  L. Ji,et al.  A ruthenium(II) β-carboline complex induced p53-mediated apoptosis in cancer cells. , 2013, Biochimie.

[7]  M. Wang,et al.  Platinum(II) complexes with mono-aminophosphonate ester targeting group that induce apoptosis through G1 cell-cycle arrest: synthesis, crystal structure and antitumour activity. , 2013, European journal of medicinal chemistry.

[8]  T. S. Guan,et al.  Synthesis of metal(II) [M = Cu, Mn, Zn] Schiff base complexes and their Pro-apoptotic activity in liver tumor cells via caspase activation , 2013, Medicinal Chemistry Research.

[9]  C. Kuo,et al.  Elucidation of the DNA-interacting properties and anticancer activity of a Ni(II)-coordinated mithramycin dimer complex , 2013, BioMetals.

[10]  M. Alexandrov,et al.  Cytostatic and cytotoxic properties of monensic acid and its biometal(II) complexes against human tumor / non-tumor cell lines , 2012 .

[11]  D. Richardson,et al.  Iron chelators for the treatment of cancer. , 2012, Current medicinal chemistry.

[12]  H. Yamada,et al.  Development of a fluorescent chelating ligand for scandium ion having a Schiff base moiety. , 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[13]  D. Richardson,et al.  The medicinal chemistry of novel iron chelators for the treatment of cancer. , 2011, Current topics in medicinal chemistry.

[14]  H. Yamada,et al.  Development of a quinazoline-based chelating ligand for zinc ion and its application to validation of a zinc-ion-coordinated compound. , 2010, Chemical & pharmaceutical bulletin.

[15]  H. Yamada,et al.  Enhancement effect of some phosphorylated compounds on fluorescence of quinazoline-based chelating ligand complexed with gallium ion , 2009 .

[16]  H. Yamada,et al.  Development of a fluorescent chelating ligand for gallium ion having a quinazoline structure with two Schiff base moieties. , 2009, Analytica chimica acta.

[17]  Bochu Wang,et al.  DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc(II) complex. , 2009, Bioorganic & medicinal chemistry.

[18]  B. Creaven,et al.  Apoptotic cell death: a possible key event in mediating the in vitro anti-proliferative effect of a novel copper(II) complex, [Cu(4-Mecdoa)(phen)(2)] (phen=phenanthroline, 4-Mecdoa=4-methylcoumarin-6,7-dioxactetate), in human malignant cancer cells. , 2007, European journal of pharmacology.

[19]  J. Ratha,et al.  Selective fluorescence zinc ion sensing and binding behavior of 4-methyl-2,6-bis(((phenylmethyl)imino)methyl)phenol: biological application. , 2007, Inorganic chemistry.

[20]  A. H. Wang,et al.  Mithramycin forms a stable dimeric complex by chelating with Fe(II): DNA-interacting characteristics, cellular permeation and cytotoxicity , 2005, Nucleic acids research.